Abstract
Immune checkpoint inhibition with the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab has improved survival in metastatic melanoma, lung cancer and renal cancer. Use of these agents holds promise in other malignancies. The augmented immune response enabled by these agents has led to a particular group of side effects called immune-related adverse events (irAEs). The main irAEs include diarrhea, colitis, hepatitis, skin toxicities and endocrinopathies such as hypophysitis and thyroid dysfunction. The anti-PD-1 antibodies have a different toxicity profile to ipilimumab with fewer high grade events. This article identifies the rates of common and uncommon irAEs associated with each immune checkpoint inhibitor (ICPI) and their timing of onset, focusing mainly on the experience in melanoma and lung cancer. An approach to management for each class of irAE is provided.
Keywords:
Immune-checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Lung cancer; Melanoma; Nivolumab; Pembrolizumab; Renal cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antilymphocyte Serum / therapeutic use
-
Antineoplastic Agents / adverse effects*
-
CTLA-4 Antigen / antagonists & inhibitors
-
Carcinoma, Renal Cell / drug therapy
-
Chemical and Drug Induced Liver Injury / drug therapy
-
Chemical and Drug Induced Liver Injury / etiology*
-
Colitis / chemically induced*
-
Colitis / drug therapy
-
Cyclosporine / therapeutic use
-
Diarrhea / chemically induced*
-
Diarrhea / drug therapy
-
Drug Eruptions / drug therapy
-
Drug Eruptions / etiology*
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Infliximab / therapeutic use
-
Ipilimumab
-
Kidney Neoplasms / drug therapy
-
Lung Neoplasms / drug therapy
-
Melanoma / drug therapy
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / therapeutic use
-
Neoplasms / drug therapy*
-
Nivolumab
-
Pituitary Diseases / chemically induced*
-
Pituitary Diseases / drug therapy
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Skin Neoplasms / drug therapy
-
Tacrolimus / therapeutic use
-
Thyroiditis / chemically induced*
-
Thyroiditis / drug therapy
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antilymphocyte Serum
-
Antineoplastic Agents
-
CTLA-4 Antigen
-
Immunosuppressive Agents
-
Ipilimumab
-
Programmed Cell Death 1 Receptor
-
Nivolumab
-
Cyclosporine
-
Infliximab
-
pembrolizumab
-
Mycophenolic Acid
-
Tacrolimus